Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Misonix Buys TheraSkin Maker Solsys Medical

Misonix Buys TheraSkin Maker Solsys Medical

Misonix, Inc., (NASDAQ: MSON) an international surgical device manufacturer, has acquired the pharmaceutical company Solsys Medical, LLC. The target company markets TheraSkin, a cellular and tissue-based product for regenerative wound healing, especially for difficult-to-heal chronic wounds. TheraSkin has been applied to more than 100,000 wounds supported by multiple clinical studies. The deal will cost Misonix a total of $117 million, comprised of $97 million in stock plus Solsys’ $20 million outstanding secured debt.  As part of the deal, Misonix will issue 5.7 million new shares. Upon closing, it will own 64% of the company and Solsys unitholders will own 36%. Misonix hopes to get... Read More »
Rehabilitation Platform ClearSky Health Hits the Ground Running

Rehabilitation Platform ClearSky Health Hits the Ground Running

ClearSky Health, a newly launched rehabilitation platform, is wasting no time on the acquisition front. Created by a partnership between Blue Wolf Capital Partners LLC and Peloton Equity LLC, and a management team led by Darby Brockette, ClearSky Health will develop and acquire inpatient rehabilitation facilities (IRFs) and related post-acute services companies. Blue Wolf Capital and Peloton Equity are focused on middle-market investments and acquisitions and have a diverse portfolio in the healthcare market. The company reported it acquired four Texas and Louisiana-based inpatient rehabilitation facilities from Maxim Management Group, LLC. The specific facilities and price terms... Read More »
AMN Healthcare Services Acquires Staffing Firm

AMN Healthcare Services Acquires Staffing Firm

AMN Healthcare Services, Inc. (NYSE: AHS), a healthcare solutions and staffing services company, has acquired Advanced Medical Personnel Services, Inc. for $200 million. Advanced Medical Personnel specializes in placing therapists and nurses in contract positions across multiple settings including hospitals, schools, clinics, skilled nursing facilities, and home health. AMN purchased Advanced Medical for the company’s recently launched telehealth platform for delivery of speech therapy to children in large school districts across the country. Another telehealth company changed hands in early April, as Advantia Health, a physician medical group, acquired Pacify, a telehealth company.... Read More »
Emergency Care Partners Buys Ascension Emergency Physicians

Emergency Care Partners Buys Ascension Emergency Physicians

Emergency Care Partners (ECP), backed by Varsity Healthcare Partners and Regal Healthcare Capital Partners, has acquired Ascension Emergency Physicians. The target provides outsourced emergency department management services to Our Lady of the Lake Ascension, formerly known as St. Elizabeth Hospital. Financial terms were not disclosed. ECP provides emergency medicine and outsourced emergency department management services to hospital facilities across Lousiana, New York, and Pennsylvania. ECP was initially formed through the joint recapitalization of Professional Emergency Medicine Management (PEMM) and Professional Emergency Physicians Associates (PEPA). The combined emergency medicine... Read More »
FSD Pharma Acquires Prismic Pharmaceuticals

FSD Pharma Acquires Prismic Pharmaceuticals

FSD Pharma Inc. (CSE: HUGE), a Canadian-based cannabis company, has acquired Prismic Pharmaceuticals Inc. a specialty pharmaceutical company focused on novel non-addictive prescription drugs for the treatment of pain, inflammation and neurological disorder. The transaction cost approximately $17.5 million, but FSD gains Prismic’s worldwide licensing rights to a patent-protected form of palmitoylethanolamide, which can increase the effectiveness while lowering the dosage amount for non-addictive prescription drugs. That lines up well FSD’s cannabinoid product portfolio. It’s a step closer to FSD’s goal of creating a platform that advances research and development of... Read More »
Health Care M&A Deals, Week Ending April 26, 2019

Health Care M&A Deals, Week Ending April 26, 2019

The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology     Acquirer Target Price Fulcrum Therapeutics Global rights to losmapimod N/A Eli Lilly and Company Global licensing for immunology medicines $20,000,000 eHealth     Acquirer Target Price Computer Programs and Systems, Inc. Get Real Health $11,000,000 Labs, MRI & Dialysis... Read More »
Healthcare Deal Volume Slipped in Q1:19

Healthcare Deal Volume Slipped in Q1:19

With 374 deals announced in the first quarter, acquisition activity was 25% lower than the 498 transactions announced in the previous quarter. Deal volume was also lower than the same quarter in 2018, down 16% compared with the 447 deals reported then. Deal volume in all four quarters of 2018 consistently closed above 440 deals, with several being added as they are discovered. While such heavy deal volume seemed to be the “new normal,” the first quarter of 2019 proved to be a reaction to the downward plunge of the equity markets late in the fourth quarter, along with chatter of a global economic slowdown and ongoing confusion over Brexit. Deal volume in the health care services category,... Read More »
Biotechnology Dominated Q1:19 Health Care Spending

Biotechnology Dominated Q1:19 Health Care Spending

Spending in the first quarter roared to nearly $150 billion, up 240% compared with the fourth quarter ($43.9 billion) and up 32% compared with the first quarter in 2018 ($113.4 billion). This quarter’s total would be halved if it weren’t for a single deal with a $74 billion price tag, Bristol-Myers Squibb’s (NYSE: BMY) acquisition of Celgene Corporation (NASDAQ: CELG). Two other deals added to the outsized total, Danaher Corporation’s (NYSE: DHR) $21.4 billion acquisition of GE Healthcare’s (NYSE: GE) Biopharma business and Centene Corporation’s (NYSE: CNC) $17.4 billion buyout of smaller health insurance rival WellCare Health Plans (NYSE: WCG). Those three deals made up 76% of the... Read More »
Deal Count Dropped in ‘Other Services,’ but Spending Shot Up

Deal Count Dropped in ‘Other Services,’ but Spending Shot Up

As we researched data across 13 sectors for our upcoming publication, The Healthcare M&A Report, First Quarter 2019, an interesting trend in the “Other Services” sector popped up. This sector includes areas ancillary healthcare services such as ambulatory surgery centers, urgent care clinics, contract research organizations (CROs), healthcare staffing companies, specialty pharmacies, among others. Since it aggregates so many healthcare services, the deal count can be high. There were 182 deals in 2018, only surpassed by numbers in the tech sectors and Long-Term Care. Last year’s totals were driven heavily by contract research organizations (CROs) and outpatient care... Read More »
Health Care M&A Deals, Week Ending April 26, 2019

Health Care M&A Deals, Week Ending April 19, 2019

The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm.   Behavioral Health Care     Acquirer Target Price Blue Sprig Pediatrics, Inc. West Texas Autism Center N/A Pinnacle Treatment Centers American Addiction Treatment Center programs N/A Biotechnology     Acquirer Target Price Castle Creek Pharmaceuticals LLC Collaboration on FCX-007... Read More »